Panagora Asset Management’s Colonnade Acquisition Corp. II Units, each consisting of one Class A ordinary share and one-fifth of one redeemable warrant CLAA.U Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-3,153
Closed -$31K 2588
2021
Q2
$31K Sell
3,153
-599
-16% -$5.97K ﹤0.01% 2118
2021
Q1
$37K Buy
+3,752
New +$37.4K ﹤0.01% 2235

Other funds holding CLAA.U

Panagora Asset Management's CLAA.U Position: Q3 2021 in Review

Panagora Asset Management sold out of Colonnade Acquisition Corp. II Units, each consisting of one Class A ordinary share and one-fifth of one redeemable warrant (CLAA.U) in Q3 2021, closing a stake of 3,153 shares — an estimated $31K sold.

Panagora Asset Management first reported a position in CLAA.U in Q1 2021 and held it in 2 quarters. The position peaked at $37K in Q1 2021. 39 funds tracked by Wall St. Rank hold CLAA.U as of Q3 2021.

  • Panagora Asset Management reported no remaining Colonnade Acquisition Corp. II Units, each consisting of one Class A ordinary share and one-fifth of one redeemable warrant position as of Q3 2021 after selling out during the quarter.
  • Panagora Asset Management sold 3,153 Colonnade Acquisition Corp. II Units, each consisting of one Class A ordinary share and one-fifth of one redeemable warrant shares in Q3 2021, an estimated $31K.
  • Panagora Asset Management first reported a position in Colonnade Acquisition Corp. II Units, each consisting of one Class A ordinary share and one-fifth of one redeemable warrant in Q1 2021 and held it in 2 quarters.
  • Panagora Asset Management's Colonnade Acquisition Corp. II Units, each consisting of one Class A ordinary share and one-fifth of one redeemable warrant position peaked at $37K in Q1 2021.
  • 39 funds tracked by Wall St. Rank held Colonnade Acquisition Corp. II Units, each consisting of one Class A ordinary share and one-fifth of one redeemable warrant as of Q3 2021.

Based on Panagora Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.